PEGylated Protein Drugs: Basic Science and Clinical Applications

Herausgegeben:Veronese, Francesco M.; Bossard, Mary J.

• Gebundenes Buch

Produktbeschreibung

PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.

Produktdetails

• Milestones in Drug Therapy
• Verlag: Birkhäuser / Birkhäuser Basel / Springer, Basel
• Artikelnr. des Verlages: 12105410, 978-3-7643-8678-8
• 2009
• Seitenzahl: 304
• Erscheinungstermin: 18. September 2009
• Englisch
• Abmessung: 241mm x 160mm x 22mm
• Gewicht: 596g
• ISBN-13: 9783764386788
• ISBN-10: 3764386789
• Artikelnr.: 24582709

Inhaltsangabe

Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century.- Protein PEGylation, basic science and biological applications.- Reactive PEGs for protein conjugation.- Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation.- Enzymatic techniques for PEGylation of biopharmaceuticals.- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites.- Protein conjugates purification and characterization.- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals.- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol).- Pegfilgrastim - designing an improved form of rmetHuG-CSF.- PEGylation of human growth hormone: strategies and properties.- PEGylated ? interferons: two different strategies to achieve increased efficacy.- Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent.- PEG: a useful technology in anticancer therapy.- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines.

---

Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century.- Protein PEGylation, basic science and biological applications.- Reactive PEGs for protein conjugation.- Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation.- Enzymatic techniques for PEGylation of biopharmaceuticals.- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites.- Protein conjugates purification and characterization.- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals.- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol).- Pegfilgrastim — designing an improved form of rmetHuG-CSF.- PEGylation of human growth hormone: strategies and properties.- PEGylated ? interferons: two different strategies to achieve increased efficacy.- Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent.- PEG: a useful technology in anticancer therapy.- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines.

Rezensionen

From the reviews:
"The volume is dedicated to the recent advances on PEGylation and PEGylated compunds. It represents an excellent update in the evolution of this field, from nanoscience to clinical applications. The book provides an excellent update in this rapidly evolving field. ... This valuable volume which will spark the interest of both researchers and clinicians contributes to a better understanding of polymer therapeutics." (Magdalena Moisei, Romanian Journal of Biochemistry, Vol. 47 (2), 2010)